Survivorship Programs Improve Quality of Life, Satisfaction in Prostate Cancer
the Cancer Therapy Advisor take:
Men with prostate cancer managed in a survivorship program report higher quality of life (QOL) and satisfaction than those who were managed by routine care, according to an article published online in Cancer.
In this study, patient-reported outcomes (PROs) such as QOL were integrated into a prostate cancer survivorship clinic and evaluated at 6 and 12 months.
Participants included 235 men being surgically treated for prostate cancer using routine follow-up care and 102 men managed in the survivorship clinic with the integrated point-of-care QOL reporting after radical prostatectomy.
Results showed that baseline QOL was comparable, but men in the survivorship groups had higher scores at 6 and 12 months than those following the routine care. For example, male patients in the survivorship clinic reported higher sexual function than those in routine care (52.2 vs 33.6 at 1 year, P<0.05).
The study suggests that disease-specific survivorship clinics with integrated QOL reporting may generate better results than clinics with routine care following cancer therapy.
Men with prostate cancer managed in a survivorship program report higher quality of life and satisfaction.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma